Meningococcal Vaccines

Safety Information

Meningococcal Disease and How to Protect Against It

Meningococcal disease can refer to any illness that is caused by the type of bacteria called Neisseria meningitidis, also known as meningococcus. These illnesses are often severe and include infections of the lining of the brain and spinal cord (meningitis) and bloodstream infections (bacteremia or septicemia). Neisseria meningitidis is a leading cause of bacterial meningitis in children 2 through 18 years old in the United States. You can protect against these diseases with safe, effective vaccination.

Meningococcal Vaccine Side Effects

Meningococcal vaccines are very safe, and they are effective at preventing meningococcal disease. Vaccines, like any medicine, can have side effects. The most common side effects with meningococcal vaccines are mild, like a sore arm, and usually last no more than 1 or 2 days.

Common Side Effects of Meningococcal Vaccine
  • Sore arm from the shot
  • Feeling tired
  • Headache

A small percentage of people who get the vaccine develop a fever.  On very rare occasions, people may have severe (anaphylactic) allergic reactions to meningococcal vaccines.

Available Meningococcal Vaccines

There are six different vaccines available in the United States to protect against Neisseria meningitidis bacteria. Which vaccine a person should get depends on their age and other factors. Some people should get one vaccine to protect against meningococcal types A, C, W, Y, and a second vaccine to protect against meningococcal type B. See CDC’s guidelines or talk to your doctor to decide which of these vaccines is right for you.

There are three vaccines to protect against Neisseria meningitidis bacteria types A, C, W, and Y:

There is one vaccine to protect against Neisseria meningitidis bacteria types C and Y intended specifically for infants and toddlers:

  • MenHibrix [PDF – 14 pages]external icon: FDA approved this vaccine in 2012. It provides protection against two meningococcal serogroups along with Haemophilus influenzae type b (Hib).  It is approved for use in children aged 6 weeks through 18 months of age.

There are two vaccines to protect against Neisseria meningitidis bacteria type B:

How CDC Monitors Vaccine Safety

CDC and FDA monitor the safety of vaccines after they are approved. If a problem is found with a vaccine, CDC and FDA will inform health officials, health care providers, and the public.

CDC uses 3 systems to monitor vaccine safety:

A Closer Look at the Safety Data

  • In 2008, reports to VAERS suggested a potential for an increased risk of Guillain–Barré syndrome (GBS) following Menactra vaccination. The package inserts for two of the meningococcal vaccines were changed to identify a history of GBS as a precaution to vaccination.  Following the VAERS study, two large safety studiesexternal icon were done to evaluate the risk of GBS after vaccination with Menactra. The two studies combined found that the risk for GBS after Menactra was not increased over the usual (non-vaccine related) GBS rate among 11 to 21 year olds.   Based on these large studies, the Advisory Committee on Immunization Practices (ACIP) no longer considers a history of GBS to be a contraindication nor precaution for meningococcal vaccination. Read more about GBS and Menactra.

Related Scientific Articles

CDC. Guillain-Barré Syndrome among recipients of Menactra meningococcal conjugate vaccine- United States, June-July 2005. MMWR. 2005 Oct 6:54(Dispatch);1-3.

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, et al. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 22 March 2013;62(RR02):1-22.

Velentgas P, Amato AA, Bohn R, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccinationexternal iconPharmacoepidemiol Drug Saf. 2012 Dec;21(12):1350-8

Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barré syndrome found after meningococcal conjugate vaccination in two large cohort studiesexternal iconPharmacoepidemiol Drug Saf. 2012 Dec;21(12):1359-60.